[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"systemic-juvenile-idiopathic-arthritis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:systemic-juvenile-idiopathic-arthritis":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100369289","phase-3-a-study-of-baricitinib-ly3009104-in-participants-from-1-year-to-less-than-18-years-old-with-systemic-juvenile-idiopathic-arthritis-sjia-100369289",false,"NCT04088396","A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)","Open-Label, Randomized Study With a Tocilizumab Reference Arm to Evaluate Safety, Efficacy and Pharmacokinetics of Baricitinib in Children From 1 to Less Than 18 Years of Age With Systemic Juvenile Idiopathic Arthritis.","Inclusion Criteria:\n\n* Participants must have a diagnosis of systemic Juvenile Idiopathic Arthritis (sJIA) as defined by International League of Associations for Rheumatology (ILAR) criteria with onset before the age of 16 years\n* Participants must have at least 2 active joints at screening and baseline\n* Cohort 1 (IL-6 inhibitor therapy naive): Participants who are at least 1 year and less than 18 years of age, except in countries that restrict use of tocilizumab in participants less than 2 years of age\n* Cohort 2 (open-label baricitinib): Participants who are at least 1 year and less than 18 years of age\n\nExclusion Criteria:\n\n* Participants must not have polyarticular JIA (positive or negative for rheumatoid factor), extended oligoarticular JIA, enthesitis-related JIA, or juvenile psoriatic arthritis\n* Participants must not have persistent oligoarticular arthritis as defined by the ILAR criteria\n* Participants must not have a history or presence of any autoimmune inflammatory condition other than JIA\n* Participants must not have active anterior uveitis or are receiving concurrent treatment for anterior uveitis\n* Participants must not have active fibromyalgia or other chronic pain conditions that, in the investigator's opinion, would make it difficult to appropriately assess disease activity for the purposes of this study\n* Participants must not have biologic features of Macrophage Activation Syndrome (MAS) over the past 12 weeks\n* Participants must not have a current or recent (\\\u003C4 weeks prior to baseline) clinically serious infection\n* Participants must not have a positive test for hepatitis B virus\n* Participants must not have evidence of active tuberculosis (TB) or untreated latent TB","ALL","1 Year","17 Years",{"count":20,"type":21},58,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","The reason for this study is to see if the study drug baricitinib is safe and effective in participants from 1 year to less than 18 years old with systemic juvenile idiopathic arthritis (sJIA). Participants are assigned to 1 of 2 cohorts. In cohort 1, participants will receive baricitinib or tocilizumab reference. In cohort 2, participants will receive baricitinib.",[27],"Systemic Juvenile Idiopathic Arthritis",[29,30,31,32,33],"Systemic","Fever","Flare","sJIA","JIA","RECRUITING","2026-06-19",{"date":37,"type":38},"2026-06-23","ACTUAL",{"date":40,"type":38},"2020-02-12",{"date":42,"type":21},"2026-09",{"name":44,"class":45},"Eli Lilly and Company","INDUSTRY",55,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":62,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":78},"100632712","a-study-on-the-use-of-canakinumab-among-familial-mediterranean-fever-and-stills-disease-patients-100632712","NCT07517250","A Study on the Use of Canakinumab Among Familial Mediterranean Fever and Still's Disease Patients","Non-interventional Study on the Use of ILARIS® (Canakinumab) Among Familial Mediterranean Fever and Still's Disease Patients Across Europe and Israel","Inclusion criteria:\n\n* Pediatric or adult patients who were prescribed canakinumab before October 2021 and received canakinumab for at least 6 months for the treatment of FMF or Still's disease (including SJIA or AOSD).\n* Have data on clinical characteristics and treatments available for at least 3 years following the initiation of canakinumab treatment.\n\nExclusion criteria:\n\n• Patients Aged \\\u003C2 Years (24 Months) at Index Date.",{"count":55,"type":21},160,"OBSERVATIONAL","This study aims to assess and characterize the treatment patterns, and long-term clinical outcomes and demographic characteristics of patients diagnosed with Familial Mediterranean fever (FMF) and Still's disease (including systemic juvenile idiopathic arthritis \\[SJIA\\] and adult-onset Still's disease \\[AOSD\\]) that received canakinumab for at least 6 months.",[59,60,27,61],"Familial Mediterranean Fever","Still Disease","Adult-Onset Still Disease",[63,64,65,66,67,68],"Canakinumab","Real-world evidence study","Treatment patterns","Clinical outcomes","Patient quality of life","Pediatric and adult patients","2026-06-05",{"date":71,"type":38},"2026-06-09",{"date":73,"type":38},"2026-03-15",{"date":75,"type":21},"2026-12-03",{"name":77,"class":45},"Novartis Pharmaceuticals",1]